Last reviewed · How we verify
rhBSSL
At a glance
| Generic name | rhBSSL |
|---|---|
| Also known as | BSSL, Bucelipase alfa, rhBSSL, bucelipase alfa (INN) |
| Sponsor | Swedish Orphan Biovitrum |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants (PHASE3)
- Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency (PHASE2)
- Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Pasteurized Breast Milk for Preterm Infants (PHASE2)
- Efficacy and Safety of Bile Salt Stimulated Lipase (BSSL) as Replacement Therapy in Infant Formula for Preterm Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhBSSL CI brief — competitive landscape report
- rhBSSL updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI